Industry News

Array BioPharma and Pierre Fabre today jointly announced top-line results from Part 1 of the Phase 3 COLUMBUS study evaluating LGX818, a BRAF inhibitor, and MEK162, a MEK inhibitor, in patients with BRAF- mutant advanced, unresectable or metastatic melanoma. The study met its primary endpoint, significantly improving progression free survival compared with vemurafenib, a BRAF inhibitor, alone. "The COLUMBUS Part 1 trial results demonstrate..."/>
Array BioPharma and Pierre Fabre Announce COLUMBUS Phase 3 Study of Encorafenib plus Binimetinib For BRAF-Mutant Melanoma Met Primary Endpoint
BioCryst Pharmaceuticals, Inc. today announced that the Company has closed a $23 million Senior Credit Facility with Midcap Financial. The facility was fully funded at closing and bears a variable interest rate based upon LIBOR, currently at 8.5%; an interest-only period through fiscal 2017; and scheduled principal and interest payments for the following..."/>
BioCryst Closes $23 Million Senior Credit Facility 
Cambrex Corporation, a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients, today announced that it has agreed to acquire PharmaCore Inc., a privately-owned company specializing in developing, manufacturing and scaling up small molecule APIs for clinical phase projects, for approximately $25 million. PharmaCore was founded in 1999 and occupies a 35,000 sq. ft. GMP site in High Point, North..."/>
Cambrex to Acquire PharmaCore Inc., to Expand Clinical Stage API Capabilities
Pfizer to Deliver on Its Purpose to Deliver Medicines and Vaccines that Significantly Impact Patients’ Lives. NEW YORK---- Pfizer Inc. announced that, after an extensive evaluation, the company’ s..."/>
Pfizer Decides Remaining One Company Best Positions Company To Maximize Future Value Creation
Vical Incorporated announced today the initiation of a Phase 2 trial of the company’ s Vaxfectin™- formulated, bivalent, therapeutic DNA vaccine for herpes simplex virus type 2 infection. The randomized, double-blind, placebo-controlled trial will evaluate the efficacy and safety of the vaccine in approximately 225 healthy adults aged 18 to 50 years with symptomatic genital HSV-2 infection at up to 15 U.S. clinical sites.. “About one in six persons between..."/>
Vical Announces Initiation of a Phase 2 Trial of Its HSV-2 Therapeutic DNA Vaccine for Genital Herpes
Exelixis, Inc. today announced that accomplished biopharmaceutical executive Julie Anne Smith has been elected to the company’ s Board of Directors. Smith’ s appointment took effect on September 22, 2016.. Smith has nearly two decades of operational leadership experience in high growth public, private, startup, and established biopharmaceutical businesses."/>
Exelixis Elects Julie Anne Smith to Its Board of Directors
Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease, and NAFLD/NASH, today announced enrollment of its..."/>
Gemphire Therapeutics Enrolls First Patient in the COBALT-1 Trial Investigating Gemcabene in Homozygous Familial Hypercholesterolemia
SciClone Pharmaceuticals, Inc. today announced two important achievements in advancing the Company's clinical pipeline and development portfolio in Greater China. The first patient has been treated in the Phase 3 trial of ZADAXIN ® in sepsis, a life-threatening infectious disease in which the drug has previously demonstrated therapeutic benefit in a Phase 2 clinical trial. The sepsis trial is a major component of SciClone's..."/>
SciClone Announces Progress In Advancing Clinical Pipeline For China Pharmaceuticals Market
Dynatronics Corporation today announced its fourth quarter results and financial results for the fiscal year ended June 30, 2016.. Net sales for the quarter increased 2.8 percent to $8.1 million, compared to $7.9 million in the same period of the prior year. Gross profit for the quarter increased 45.1 percent representing 33.0 percent of sales, compared to 23.4 percent of sales for the quarter ended June 30, 2015."/>
Dynatronics Announces Fourth Quarter and Fiscal Year 2016 Financial Results
Cigna Foundation Workplace Wellness Summit taking place Oct. 11 from 8 a.m. to 1 p.m. at the Jumeirah Emirates Towers Hotel, Sheikh Zayed Road, Dubai, United Arab Emirates. Employers, NGOs, academicians, medical professionals and others with an interest in workforce health and well-being are invited. Seated is limited, and there is..."/>
Cigna Foundation Workplace Wellness Summit Set for Oct. 11 in Dubai; Leading Dubai Employers to Discuss Health, Well-being of Workforce
Exelixis--. SOUTH SAN FRANCISCO, Calif.---- Exelixis, Inc. today announced that its partner Daiichi Sankyo Company, Limited has initiated a phase 3 pivotal trial to evaluate CS-3150, an oral, non-steroidal, selective mineralocorticoid..."/>
Exelixis Announces Collaborator Daiichi Sankyo’s Initiation of Phase 3 Clinical Development for CS-3150, a Selective Mineralocorticoid Receptor Antagonist
Acorda Therapeutics, Inc. has the right to redeem the minority shares in Biotie Therapies Corp. and that Acorda has the right to obtain title to the minority shares by lodging a security approved by the Arbitral Tribunal for the payment of the redemption price and the interest accruing thereon. Pursuant to the confirmation of the redemption right, Nasdaq..."/>
THE ARBITRAL TRIBUNAL HAS CONFIRMED ACORDA THERAPEUTICS, INC.’S REDEMPTION RIGHT REGARDING THE SHARES IN BIOTIE THERAPIES CORP. AND PUBLIC TRADING IN THE SHARES HAS BEEN TERMINATED
Avagenesis Corp. and Avapecia standardized adipose stem cell..."/>
Liberty Biopharma Receives Notice of Patent Allowance for Israel
Sun Pharmaceutical Industries Ltd, the Federation of Medical and Sales Representatives' Associations of India, has announced one-day strike by over 500 Sun Pharma sales representatives on Monday. Sun Pharma and FMRAI, the largest union of medical sales representatives in India, have locked their horns for the past year after Sun Pharma allegedly transferred and demoted some..."/>
Sun Pharma sales staff on strike over pending wages [Mint, New Delhi]
Bionor Pharma ASA regarding the primary insider notification from certain primary insiders of the Company that have received Subscription Rights in the Rights Issue."/>
Bionor Pharma ASA : Primary inside Notification - Maja A. Sommerfelt
Bionor Pharma ASA regarding the primary insider notification from certain primary insiders of the Company that have received Subscription Rights in the Rights Issue."/>
Bionor Pharma ASA : Primary insider notification - Gunnar Flåten
Bionor Pharma ASA."/>
Bionor Pharma ASA : Primary insider notification - Unni Hjelmaas
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration has accepted for priority review the Biologics License Application for dupilumab for the treatment of adult patients with inadequately controlled moderate-to-severe atopic dermatitis, a serious, chronic inflammatory skin disease. The application has been given a Prescription Drug User Fee Act target action date of..."/>
Regeneron and Sanofi Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA
Galapagos NV reports that Dr Severine Vermeire, principal investigator of the FITZROY Phase 2 study with investigational agent filgotinib in Crohn's disease, will present endoscopic and other key findings from the study in an oral session during United European Gastroenterology Week in Vienna, Oct. 15- 19, 2016. The abstract for the talk is available online at www.ueg.eu/week/.. The FITZROY Phase 2 study randomized 174 patients with Crohn's..."/>
Endoscopic improvements with filgotinib are consistent with clinical remission rates in patients with Crohn's disease
Galapagos NV reports that Dr Severine Vermeire, principal investigator of the FITZROY Phase 2 study with investigational agent filgotinib in Crohn's disease, will present endoscopic and other key findings from the study in an oral session during United European Gastroenterology Week in Vienna, Oct. 15- 19, 2016. The abstract for the talk is available..."/>
Endoscopic improvements with filgotinib are consistent with clinical remission rates in patients with Crohn's disease
Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of novel..."/>
Corvus Pharmaceuticals Announces Preclinical and Preliminary Clinical Biomarker Data of Lead Oral Checkpoint Inhibitor CPI-444 Presented at Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, today announced that the Chicago Board Options Exchange has listed options for MediciNova common stock.. CBOE is the largest U.S. options exchange and the creator of listed options. Additional information about CBOE and its products is available at the CBOE website at www.cboe.com."/>
Options on MediciNova Common Stock Listed on CBOE
Itamar Medical, was closely watching what was on the plate of his eight-and-a-half year old niece Ofri, who had a weight problem and a methylphenidate prescription, which caused her to have difficulty in focusing and performing well in school. Her parents had several times been scolded that they were not sufficiently strict about making the girl eat less. "My doctors also pressured me, telling me I ate too much",..."/>
Itamar Medical - a sleeping giant? [Globes, Tel Aviv, Israel]

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology656 Articles
Consumer Discretionary621 Articles
Financials404 Articles
Industrials387 Articles
Health Care365 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.